Gilead Sciences (XSGO:GILD) COGS-to-Revenue : 0.23 (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Gilead Sciences COGS-to-Revenue?

Gilead Sciences's Cost of Goods Sold for the three months ended in Mar. 2025 was $1,540 Mil. Its Revenue for the three months ended in Mar. 2025 was $6,667 Mil.

Gilead Sciences's COGS to Revenue for the three months ended in Mar. 2025 was 0.23.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Gilead Sciences's Gross Margin % for the three months ended in Mar. 2025 was 76.90%.

Gilead Sciences COGS-to-Revenue Historical Data

The historical data trend for Gilead Sciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences COGS-to-Revenue Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.19

0.24

0.21

0.24

0.22

Gilead Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.23	0.22	0.21	0.21	0.23

Gilead Sciences COGS-to-Revenue Calculation

Gilead Sciences's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	6251	/	28754
	=	0.22

Gilead Sciences's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1540	/	6667
	=	0.23

Gilead Sciences (XSGO:GILD) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Gilead Sciences's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1540 / 6667
	=	76.90 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Gilead Sciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (XSGO:GILD) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD:Canada GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).